Network meta-analysis of 6,025 patients: obicetrapib outperforms bempedoic acid for LDL-C lowering on top of statins by 15 percentage points (J Clin Lipidol 2026)

Background: Many patients receiving maximally tolerated statins fail to achieve recommended low-density lipoprotein cholesterol (LDL-C) levels, and multiple add-on nonstatin therapies are now available or in development, including obicetrapib and bempedoic acid. However, no direct comparison between these drugs is available.

Objective: We conducted a network meta-analysis of randomized, double-blind, placebo-controlled trials evaluating obicetrapib or bempedoic acid on top of statin therapy.

Methods: We conducted a network meta-analysis of randomized, double-blind, placebo-controlled trials evaluating obicetrapib or bempedoic acid on top of statin therapy. The primary outcome was the mean percentage change in LDL-C from baseline vs placebo. The secondary outcome was the mean percentage change in non-high-density lipoprotein cholesterol (non-HDL-C), treatment safety, including adverse events, serious adverse events, and cardiovascular composite endpoint. A random-effects model was used to synthesize evidence, test consistency, and generate treatment rankings. Heterogeneity and publication bias were also assessed.

Results: Six trials involving 6025 participants met the inclusion criteria. Obicetrapib resulted in a pooled LDL-C reduction of -33.17% (95% CI, -36.21 to -30.13) vs placebo, whereas bempedoic acid produced a reduction of -18.02% (95% CI, -18.83 to -17.21). The comparison of treatments showed an additional 15.15% in LDL-C reduction, favoring obicetrapib (95% CI, -18.30 to -12.00). There was no evidence of heterogeneity or inconsistency across the network (τ² = 0; I² = 0). Obicetrapib also showed a greater non-HDL-C reduction of -16.1% (95% CI, -19.1 to -13.1). Both drugs showed a comparable safety profile. Findings were consistent across multiple sensitivity analyses. No evidence of publication bias was detected.

Conclusion: Among statin-treated patients requiring further LDL-C lowering, obicetrapib may represent an additional oral option to achieve the LDL-C target. Results should be interpreted in the context of currently available cardiovascular outcomes evidence, pending dedicated outcomes and long-term safety data.